on Galimedix, Inc.
Galimedix Therapeutics Advances Alzheimer's Development Strategy at CTAD 2026
Galimedix Therapeutics, a Phase 2 biotechnology firm, revealed its plans for developing GAL-101 for Alzheimer's at the CTAD 2026 in Boston. The company aims to establish GAL-101's efficacy in Down syndrome-associated Alzheimer's disease, while also advancing trials in the general Alzheimer's population through a Phase 2a biomarker-driven study named SAPHARY.
This study will enroll 100 patients with mild to moderate Alzheimer's to evaluate GAL-101's safety, efficacy, and pharmacokinetics/predictive dynamics parameters. The test will analyze EEG readouts, fluid biomarkers, and cognition endpoints. Pre-clinical results show GAL-101 can target and eliminate toxic amyloid beta species linked to neurodegenerative diseases, offering potential symptomatic relief without causing major side effects.
GAL-101's development extends to other conditions like dry age-related macular degeneration and glaucoma. Galimedix's strategic approach aims at offering new viable treatments for diseases with limited options.
R. H.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galimedix, Inc. news